Over the last quarter century investigators have demonstrated that allogeneic hematopoietic
cell transplantation (HCT) can cure chronic myelogenous leukemia (CML). Early reports …

Patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute
lymphoblastic leukemia express BCR-ABL, a constitutively active tyrosine kinase that is the …

STI571 (imatinib; Gleevec®) został zaprojektowany jako inhibitor kinazy Bcr-Abl, białka
onkogennego odpowiedzialnego za rozwój przewlekłej białaczki szpikowej (CML). Jest …

385 hematopoietic stem cells. 13, 14 The Ph chromosome (22q–) results from the reciprocal
translocation of the distal parts of the long arms of chromosomes 9 and 22 (Fig. 17.1). The …

The extraordinary success of imatinib for the treatment of chronic myeloid leukemia (CML),
gastrointestinal stromal tumors and subgroups of patients with hypereosinophilic syndrome …

Background Tyrosine kinase inhibitors (TKIs) are the recommended treatment for patients
with chronic myeloid leukemia (CML). The MDR1/ABCB1 gene plays a role in resistance to …

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph)
chromosome (22qÀ) that results from at (9; 22)(q34; q11) reciprocal translocation (1, 2) …

The RET gene encodes a transmembrane tyrosine kinase, that plays a crucial role in
regulating cell proliferation, migration, differentiation, and survival. Activating mutations in …

The discovery of a translocation between the Abelson oncogene (ABL1) on the long arm of
chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22 resulting in the …

Background: The clinical success of the tyrosine kinase inhibitor imatinib (Gleevec; STI-571)
in the treatment of several leukemias has emphasized the proof-of-concept that molecularly …